Trypanosoma cruzi is the protozoan parasite that causes Chagas disease, an illness that affects millions in the western hemisphere from Argentina to Canada. People can become infected with T. cruzi through the bite of its reduviid bug vector or through several other means, including maternal-fetal transmission and blood transfusion. Chagas manifests as a chronic cardiomyopathy in approximately one-third of infected individuals and is the leading cause of infectious myocarditis in the world. Others develop megadisease of the esophagus or colon. The two drugs used to treat T. cruzi infection, Nifurtimox and Benznidazole (Bz), have been the mainstay of therapy for decades, with no significant improvement to their well-documented neurotoxicity and carcinogenicity. Chagas is thus a silent epidemic that is in dire need of more advanced treatment options. We have developed a novel nanocarrier formulation (nanoBz) that permits the delivery of parasiticidal drugs that effectively kill T. cruzi parasites at 166-fold lower concentrations than required by the current free drug formulation. The goals of our proposed research are:
Aim 1. To determine how the cellular biodistribution of nanoBz influences its trypanocidal activity during acute T. cruzi infection.
Aim 2. To validate the sustained delivery of nanoBz for prophylactic and therapeutic treatment of chronic T. cruzi infection.

Public Health Relevance

Chagas disease is an infection that affects millions of people in the western hemisphere from Canada to Argentina, damaging the heart, colon and esophagus, and imposing an economic burden on the world greater than cholera or cervical cancer. The current drugs for treating Chagas are moderately effective but suffer from tremendous toxicity that often require the physician to stop treatment. Our research focuses on nanotechnology, the formulation of tiny particles containing drugs, to develop a better formulation that is more effective than the current drugs AND greatly reduces toxicity in hopes of helping the millions of people with this serious infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI144529-01
Application #
9727764
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
O'Neil, Michael T
Project Start
2019-03-06
Project End
2021-02-28
Budget Start
2019-03-06
Budget End
2020-02-29
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Cedars-Sinai Medical Center
Department
Type
DUNS #
075307785
City
Los Angeles
State
CA
Country
United States
Zip Code
90048